Skip to main content

Table 1 Baseline demographic, clinical and laboratory data of the study population

From: Emerging markers of cachexia predict survival in cancer patients

Parameters

Cancer group

HS group

Follow up (18 months)

   

Death

Survivors

P

 

n:140

n: 30

n:94 (67%)

n:46 (33%)

 

Age, y

61.8 ± 14.3

59.6 ± 12.2

67.4 ± 6.3

60.7 ± 8.9

0.01

Weight change, %

12.1 ± 8.9

-

18.6 ± 1.8

7.6 ± 2.3

< 0.0001

Tot cholesterol (mg/dL)

142.9 ± 27.2

175.6 ± 12.6

139.6 ± 9.6

141.6 ± 10.6

0.23

Diabetics, n

28 (20%)

-

18

10

0.10*

Hypertension, n

52 (37%)

-

30

22

0.19*

Heart Failure, n

16 (11%)

-

10

6

0.29*

CKD, n

56 (40%)

-

37

19

0.003

Hemoglobin, g/dl

10.1 ± 2.5

13.6 ± 1.7

9.3 ± 1.6

10.8 ± 1.8

< 0.0001

Metastatic disease, n

105 (75%)

-

90

15

<0.0001*

Albumin, g/L

2.7 ± 0.6

4.02 ± 0.8

2.3 ± 0.4

2.5 ± 0.5

0.004

Obestatin, ng/ml

17.4 ± 7.1

24.8 ± 5.5

12.3 ± 2

15.1 ± 4.8

0.005

Leptin, ng/ml

38.4 ± 21.2

76.2 ± 17.4

21.8 ± 10

33.8 ± 9.1

< 0.0001

Ghrelin ng/ml

573.3 ± 130

320.2 ± 66.8

657.6 ± 88

481.4 ± 43.6

< 0.0001

  1. P values calculated by using the t test, except where indicated.
  2. *Calculated by using x 2 test.
  3. Abbreviations: HS healthy subjects, CKD chronic kidney disease, defined as glomerular filtration rate <60 ml/min.